Cyrano Therapeutics, Inc. Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2014

Location

FL US

Primary Industry

Pharmaceuticals

About

Based in Washington, US, and founded in 2014, Cyrano Therapeutics, Inc., operates as a pharmaceutical company that develops therapeutic solutions for olfactory dysfunction, a condition that limits the ability to taste and smell. In November 2020, Cyrano Therapeutics, Inc. raised USD 4.08 million in Series A funding, co-led by investors Lumira Ventures and Remiges Ventures. As of 2022, the company is led by its CEO and President, Rick Geoffrion. The company offers regenerative medicine for loss of smell and flavor function. The company has created a proprietary intranasal product to help patients with chronic loss of taste and smell regain function. The company is working to determine an optimal dose and validate the therapy in a double-blind, randomized setting.

Current Investors

Remiges Ventures, Lumira Ventures, DeepWork Capital

Request a demo to show more

Primary Industry

Pharmaceuticals

Sub Industries

Biopharmaceuticals, Pharmaceutical Research & Development

Website

www.cyranotherapeutics.com

Company Stage

Series B

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.